Item 2.02. Results of Operations and Financial Condition.
On November 29, 2006, Cadence Pharmaceuticals, Inc. issued a press release announcing its
financial results for the quarter ended September 30, 2006. A copy of this press release is
attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2. of Form 8-K, the information in this Current
Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liability of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
| Exhibit | ||
| Number | Description of Exhibit | |
99.1
|
Press Release dated November 29, 2006. |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 1, 2006 | CADENCE PHARMACEUTICALS, INC. |
|||
| By: | /s/ David A. Socks | |||
| Name: | David A. Socks | |||
| Title: | Vice President, Business Development | |||
-3-
EXHIBIT INDEX
| Exhibit | ||
| Number | Description of Exhibit | |
99.1
|
Press Release dated November 29, 2006. |
-4-
